References
Lyman, S. Xconomy/Seattle (18 January 2011) <http://www.xconomy.com/seattle/2011/01/18/what-does-biotech-really-suffer-from-information-overload-or-underload/?single_page=true>
Kling, J. Nat. Biotechnol. 29, 197–200 (2011).
Samaha, L. Investing by Suite 101 (9 July 2010) <http://www.suite101.com/content/estimating-drug-probabilities-of-success-in-fda-clinical-trials-a259518>
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Lyman, S. Industry access to the literature. Nat Biotechnol 29, 571–572 (2011). https://doi.org/10.1038/nbt.1909
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1909
- Springer Nature America, Inc.
This article is cited by
-
Literature access and destruction
Nature Biotechnology (2013)